What question did this study set out to answer?

This study aims to evaluate the efficacy of emapalumab as a treatment for high-grade cytokine release syndrome in pediatric patients following CAR-T cell therapy.

March 7, 2026Open Access

Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy

Key Points

This study aims to evaluate the efficacy of emapalumab as a treatment for high-grade cytokine release syndrome in pediatric patients following CAR-T cell therapy.
Conducted a retrospective analysis of clinical and laboratory parameters in pediatric patients
Included 38 patients who failed low-dose glucocorticoids and/or tocilizumab therapy
Measured clinical symptoms, inflammatory markers, and CAR-T cell counts
Emapalumab significantly reduced clinical symptoms and inflammatory marker levels
Average temperature dropped from 39.61°C to 38.38°C, P < 0.001
Inflammatory markers such as IL-2, IL-10, TNF-α, and IFN-γ showed substantial reduction
Median event-free survival (EFS) and overall survival (OS) rates at 6 months were 76.9% and 80.1%, respectively
No direct safety risks related to emapalumab were observed

Abstract

Background Chimeric antigen receptor T (CAR-T) cell therapy significantly improves the prognosis of a variety of hematological malignancies; however, its broader application in clinical practice is hindered by adverse events, particularly cytokine release syndrome (CRS). Moreover, the selection of treatment strategies for patients with high-grade CRS must be meticulously tailored. Emapalumab, a fully human IgG1 monoclonal antibody targeting IFN-γ, has been proposed to have clinical benefit in CRS. Methods In this retrospective study, we conducted a comprehensive analysis of clinical and laboratory parameters in 38 pediatric patients who failed low-dose glucocorticoids monotherapy, tocilizumab monotherapy or glucocorticoid-tocilizumab combination therapy, following treatment with investigational CAR-T products. Results Emapalumab significantly improved both clinical symptoms and laboratory parameters. The rapid decrease in mean temperature (39.61 vs. 38.38°C, P 0.001) and levels of inflammatory markers including IL-2 (32.35 vs. 11.94 pg/ml, P 0.001), IL-10 (222.29 vs. 86.09 pg/ml, P = 0.018), TNF-α (4.17 vs. 2.94 pg/ml, P = 0.032), and IFN-γ (21984.11 vs. 674.87 pg/ml, P 0.001) indicated the remarkable scavenging efficacy of emapalumab against cytokine storm following CAR-T therapy. Additionally, both mean CAR-T cell counts (549.95 vs. 8.16 cell/μl, P 0.001) and the ratio of CAR-T to CD3+ (11.3% vs. 36.54%, P 0.001) in peripheral blood increased significantly, demonstrating that the administration of emapalumab didn’t seem to have a significant negative impact on the proliferation of CAR-T cells. The median EFS and OS were both not reached, with an EFS rate of 76.9% (95%CI, 63.8-92.6) and with an OS rate of 80.1% (95% CI, 67.7-94.6) at 6 months. Throughout the treatment course, no direct evidence of emapalumab-related safety risks was observed. Conclusion Emapalumab seems to serve as an effective salvage therapy for patients experiencing high-grade CRS with inadequate response to low-dose glucocorticoids and/or tocilizumab following CAR-T therapy. These data supported the use of emapalumab in high-grade CRS as well as provide rationale for future prospective studies.

Bookmark

View Full Paper

Cite This Study

Zhang et al. (Wed,) studied this question.

synapsesocial.com/papers/69abc0b85af8044f7a4e96c4 https://doi.org/https://doi.org/10.3389/fimmu.2026.1679175

Bookmark

View Full Paper